StemCells, a biopharmaceutical company, researches, develops, and commercializes cell-based therapeutics and related technologies for stem cell-based research and drug discovery and development. It engages in clinical development of its platform technology, HuCNS-SC, a purified human neural stem cells used as a potential treatment for disorders of the central nervous system.

Alleged Wrongful Conduct

Kessler Topaz Meltzer & Check LLP is investigating whether StemCells’ executive officers and directors breached their fiduciary duties to the company with respect to certain strategic financial and operational decisions, and whether those decisions harmed StemCells and its shareholders.

If you currently own shares of StemCells, Inc. (NYSE: STEM) and would like to learn more about our investigation, please fill out our online form or contact us today at 888-299-7706 or via email at info@ktmc.com.